Arch Therapeutics Stock Net Income
| ARTHDelisted Stock | USD 0.0001 0.00 0.00% |
As of the 9th of February, Arch Therapeutics shows the mean deviation of 74.72, and Risk Adjusted Performance of 0.0997. Arch Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Arch Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Arch Therapeutics' valuation are provided below:Arch Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Arch |
Search Suggestions
| AR | Antero Resources Corp | Company |
| AR | Arweave | Cryptocurrency |
| ARR-PC | ARMOUR Residential REIT | Company |
| ARDC | Ares Dynamic Credit | Fund |
| ARB | AltShares Trust | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Arch Therapeutics reported net income of (5.28 Million). This is 101.55% lower than that of the Health Care Equipment & Supplies sector and 107.53% lower than that of the Health Care industry. The net income for all United States stocks is 100.92% higher than that of the company.
Arch Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Arch Therapeutics could also be used in its relative valuation, which is a method of valuing Arch Therapeutics by comparing valuation metrics of similar companies.Arch Therapeutics is currently under evaluation in net income category among its peers.
Arch Fundamentals
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 | |||
| Operating Margin | (364.73) % | |||
| Current Valuation | 12.54 M | |||
| Shares Outstanding | 249.94 M | |||
| Shares Owned By Insiders | 14.58 % | |||
| Price To Earning | (16.36) X | |||
| Price To Book | 34.61 X | |||
| Price To Sales | 638.65 X | |||
| Revenue | 15.65 K | |||
| Gross Profit | (35.84 K) | |||
| EBITDA | (4.71 M) | |||
| Net Income | (5.28 M) | |||
| Cash And Equivalents | 55 K | |||
| Total Debt | 2.81 M | |||
| Debt To Equity | 2.62 % | |||
| Current Ratio | 0.82 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (4.46 M) | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 3.0 | |||
| Beta | 0.72 | |||
| Market Capitalization | 1.44 B | |||
| Total Asset | 2.6 M | |||
| Retained Earnings | (35.9 M) | |||
| Working Capital | 14.96 K | |||
| Current Asset | 18.02 K | |||
| Current Liabilities | 3.06 K | |||
| Net Asset | 2.6 M |
About Arch Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Arch Pink Sheet
If you are still planning to invest in Arch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Arch Therapeutics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |